Beauty IPO Window Reopens in Hong Kong: What It Means for You

Twenty-eight beauty companies are queueing to go public in 2026. Most of them say the money is for going abroad. If you sell skincare or fragrance in Europe or North America, that sentence is about you, and almost nobody in our industry has read it that way yet.

The facts

According to a 36Kr count published this summer, 28 companies across the Chinese beauty value chain were at some stage of an IPO process in the first half of 2026. Not 28 brands: raw material suppliers, packaging makers, brands, e-commerce operators, retailers and testing labs. The whole chain at once.

The split matters. Upstream players, ingredient and peptide makers, are listing on the mainland A-share and Beijing exchanges, where approval is faster and valuations kinder. Brands and service companies are going to Hong Kong. Eight of them filed or were in process there in the first half alone.

Proya filed with the Hong Kong Stock Exchange on 30 April 2026, its second attempt after an October 2025 filing lapsed. It is seeking an A+H dual listing, with CICC and UBS as joint sponsors. Proceeds are earmarked for R&D, capacity and overseas expansion. Marubi is doing the same A+H manoeuvre. Chando, through its Jala parent, refiled in Hong Kong on 2 April 2026 after its first attempt expired unheard; L’Oréal holds 6.67% of it, bought for RMB 442 million, a stake the Chinese securities regulator asked questions about.

The two names people cite as proof this works are already listed, and that is the more useful half of the story. Shanghai Forest Cabin, the camellia oil brand known in China as Lin Qingxuan, listed on 30 December 2025 at HKD 77.77 a share and closed its first day around HKD 85, near HKD 12 billion of market value. It is the only Chinese brand inside China’s top 15 premium skincare labels by 2024 retail sales, at 1.4% share. Eternal Beauty Holdings, the distributor that runs Hermès, Van Cleef & Arpels and Chopard fragrance in Greater China, listed on 26 June 2025 and broke its issue price on day one, closing 16.7% below the HKD 2.88 offer.

PwC expects Hong Kong to take HKD 320 to 350 billion in IPO proceeds across 2026, with consumer among the lead sectors. Some bankers think the queue runs into 2027.

What this actually means

Strip out the excitement and three things are true at once.

First, the capital is real and it is pointed outward. Proya’s founder has said publicly that he wants a global top ten beauty group, which needs roughly RMB 50 billion of annual revenue, and that the plan includes buying European brands with history and technology. He is not improvising. Proya took 51% of Flower Knows across August 2025 and May 2026 for about RMB 779 million, and Flower Knows was already growing fastest outside China. S’Young bought Evidens de Beauté in 2022 and RéVive in 2024. Ushopal has assembled Juliette Has A Gun, Payot, Bonpoint Beauté and ARgENTUM. The listing is the financing leg of a strategy that has been running for four years.

Second, the market is picky, and that is healthy. Eternal Beauty broke issue. Six of the 28 stalled on expired prospectuses or accounting disclosure. Chando refiled because nobody turned up for the first hearing. Hong Kong investors are not writing blank cheques to anything with a lipstick in the deck.

Third, and this is the part the Chinese coverage says out loud and the Western coverage does not: the reason these groups are raising in Hong Kong rather than at home is that they need foreign currency, offshore acquisition vehicles and a listed equity story they can wave at a French or Italian founder. Hong Kong dollars buy things outside China. A-share renminbi does not, easily.

Read Proya’s own numbers before you panic, though. In 2025 the company spent about half its revenue on sales and roughly 2% on R&D, against RMB 10.6 billion of turnover. This is not a research powerhouse buying you for your lab. It is a marketing machine buying credibility, formulas and a Western address.

What it changes for your brand

Two mechanical consequences, and they pull in opposite directions.

Your acquisition cost in China is going up. Not next month. Over the next four to six quarters, as listing proceeds land and get spent. A newly listed brand with fresh capital and a stated international mandate buys Xiaohongshu and Douyin inventory in the same auctions you do, and it buys at a price that makes sense for someone answering to public shareholders rather than to a cash flow statement. We saw this exact pattern after the 2021 cohort of C-beauty listings. CPM in beauty categories moved, and it did not move back.

Your resale value is going up too. If you own a niche skincare or fragrance house with real formulation, a clean cap table and any Chinese revenue at all, you are now looking at a buyer pool that has genuinely widened. Huxiu ran a piece this year on Chinese capital shifting from buying identity to buying revaluable assets, and that shift is the whole point. Five years ago a Chinese group bought a European brand for the logo. Now they buy it because they can put RMB 300 million of media behind it in a market you cannot reach and triple the revenue. That arithmetic supports a higher multiple than yours today.

Share of the Chinese beauty market is what listing proceeds are bought with. Every point a newly funded domestic group takes comes out of an imported brand’s line.

Who this does not concern: if you have no China presence, no Chinese entity, no registered products and no intention of building any, none of this reaches you this year. Do not let a banker tell you otherwise.

What to do about it, in order

One. Register. NMPA filing takes months you do not get back, and every conversation above, media, distribution, acquisition, starts with legally sellable products. This is administrative, not strategic, and it is the single most common thing I find missing.

Two. Build the part that does not inflate. Owned content on Xiaohongshu, a WeChat account with actual returning readers, Chinese-language search presence. When media costs rise, brands with an owned audience keep selling and brands renting attention stop.

Three. Get one honest Chinese revenue number. One channel, one year, unsubsidised. Cross-border e-commerce is enough. That number is your defence in a media auction and your leverage in an acquisition conversation. See how independent beauty brands enter China on small budgets before you commit to anything larger.

Four. Watch who lists and what they buy. Read the prospectuses, they are public and specific about use of proceeds. A brand that raises for overseas acquisition tells you, in writing, the categories it is hunting. If that is your category, you have your answer about whether to expect a competitor or a phone call. Context on the players is in our notes on the rise of C-beauty and on the distributors who control fragrance in China.

Five. If you are being approached, and more of you will be, price the strategic value, not the multiple your accountant found. What a Chinese listed group can do with your formula in their home market is worth more than what you can do with it in yours. Say so out loud in the room.

The open question

Some founders I respect think selling a minority stake to a newly listed Chinese group is the only realistic way a small European brand gets scale in China, and that refusing it is vanity. Others say the moment you take that money you lose control of your positioning in your home market, permanently, and no China revenue compensates for that. I lean towards the second, and I am not certain. Which way do you lean, and what would change your mind?